Philip Loury, University of California San Diego
The treatment of the Human Immunodeficiency Virus strain HIV-1 requires close monitoring of patient viral load in order to verify that treatment is successfully inhibiting replication of the retrovirus. The impact of HIV drug resistance (DR) following the initiation of first-line antiretroviral therapy (ART) is an emerging issue of critical importance to the success of HIV treatment in developing countries. Hospitals in developing nations cannot afford such testing or lack personnel and equipment for proper sample preparation and analysis. In order to confront this challenge, the Engineering World Health chapter at UCSD has launched a project to design a cost-effective point-of-care solution to screen HIV patients for ART drug resistance, thus enabling hospitals and clinics in the developing world to better diagnose and appropriately treat their patients.
Chairman Chatter: Embracing the Challenge
Tuesday, 20 Sep 2016 19.09
Women in Pharma Debuts at 2016 ISPE Annual Meeting & Expo
Tuesday, 20 Sep 2016 14.09
You’re All HEROES! Two Powerful Pharma Keynote Messages
Tuesday, 20 Sep 2016 02.09